Feedback
Settings

Settings

Goto Application

666,749 results
Offices all Languages en Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12Q

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 66,675
1.WO/2026/026937SIRNA FOR INHIBITING HSD17B13 GENE EXPRESSION, AND MODIFICATION AND USE THEREOF
WO - 05.02.2026
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/CN2025/112029 Applicant FRONTIER BIOTECHNOLOGIES INC. Inventor WANG, Michael Zhiyan
Provided are an siRNA for inhibiting HSD17B13 gene expression, and a modification and a use thereof, belonging to the technical field of biopharmaceuticals. The double-stranded RNA molecule is an siRNA, and the siRNA comprises a sense strand and an antisense strand at least partially forming a double-stranded region, the sense strand comprising a nucleotide sequence that is any odd-numbered sequence from sequences 1-394. The aforementioned siRNA can efficiently degrade HSD17B13 mRNA and significantly reduce HSD17B13 protein levels, and can be used to prepare a novel drug for treating diseases caused by abnormal HSD17B13 expression, including but not limited to fatty liver, NAFLD, and NASH.
2.WO/2026/025197NON-AQUEOUS COMPOSITIONS FOR STORAGE AND/OR STABILIZATION OF NUCLEIC ACID AND METHODS OF USE THEREOF
WO - 05.02.2026
Int.Class C12Q 1/6806
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction assay
 Appl.No PCT/CA2025/051032 Applicant DNA GENOTEK INC. Inventor WOOD, Cameron Gary
The present application provides a non-aqueous storage composition for use in storage or stabilization of nucleic acid from or in biological samples. The non-aqueous storage composition comprises a non-aqueous solvent that comprises: dimethylsulfoxide, a glycol, glycerol or a mixture of two or more thereof; one or more surfactant; a buffer to provide a pH in the range of from about 4 to about 8; and, optionally, a chelator. Also provided herein are methods and kits for storage or stabilization of nucleic acid from or in biological samples. Further provided herein are methods and kits for concentration of nucleic acid or other analyte(s) of interest from a liquid biological sample using the non-aqueous storage composition.
3.WO/2026/026922USE OF RINL GENE AND ANTAGONIST THEREOF IN TREATMENT OF OBESITY
WO - 05.02.2026
Int.Class A61K 45/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
 Appl.No PCT/CN2025/111832 Applicant XIAMEN UNIVERSITY Inventor ZUO, Zhenghong
The use of an RINL gene and an antagonist thereof in the treatment of obesity. Specifically provided is the use of an RINL gene or an encoded protein thereof. The RINL gene or the encoded protein thereof is used for one of the following: (1) as a marker for diagnosing, detecting or prognosing obesity; (2) in the preparation of a reagent or kit for diagnosing or detecting obesity; or (3) in the preparation of a drug for treating obesity. RINL-KO significantly improves glucose tolerance and insulin resistance of obese mice, ameliorates the accumulation of subcutaneous fat and visceral fat thereof, alleviates the inflammation of adipose tissue thereof, and greatly improves the health of the mice. Therefore, an RINL antagonist has the potential to efficiently treat obesity. It is proposed for the first time that RINL is used as a new target in the preparation of a drug for treating obesity, which is of great significance for new drug screening, and also provides a new idea for the treatment of obesity.
4.WO/2026/027357BIOMARKERS AND METHODS FOR THE EARLY DETECTION OF HEPATOCELLULAR CARCINOMA
WO - 05.02.2026
Int.Class C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
 Appl.No PCT/EP2025/071103 Applicant SIEMENS HEALTHINEERS AG Inventor KANNE, Julian
The present invention relates to a composition for diagnosing, detecting, or monitoring a liver cancer disease, comprising nucleic acid affinity ligands and/or peptide affinity ligands for a group of biomarkers comprising at least Prolactin, Alpha Fetoprotein (AFP) and Interleukin-6 (IL-6) and, optionally, further comprising one or more of Squamous Cell Carcinoma Antigen (SCC), Metallopeptidase Inhibitor 1 (TIMP-1) and CYFRA 21-1. The present invention further envisages corresponding methods for diagnosing, detecting or monitoring a cancer disease in a subject, as well as a computer-implemented method for the analysis of a sample of a subject, a computer-implemented method for providing a trained machine learning model, the use of affinity ligands for detecting, diagnosing, or monitoring a liver cancer disease, in particular early forms of liver cancer.
5.WO/2026/028902DIAGNOSTIC AGENT, PANCREATIC CANCER DIAGNOSIS KIT, DETECTION METHOD, MARKER, ANTI-PANCREATIC CANCER AGENT, AND COMPOSITION FOR TREATING PANCREATIC CANCER
WO - 05.02.2026
Int.Class G01N 33/53
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
 Appl.No PCT/JP2025/026150 Applicant THE JIKEI UNIVERSITY Inventor SHIMAMOTO, Nana
A diagnostic agent for pancreatic cancer, the diagnostic agent comprising: a primer set for amplifying SLC12A7 DNA or mRNA in a sample derived from a subject; and/or a probe that binds to the SLC12A7 DNA, mRNA or an amplification product thereof, or an antibody that binds to SLC12A7 protein. An anti-pancreatic cancer agent comprising an SLC12A7 inhibitor as an active ingredient.
6.WO/2026/030582ASSESSING AND TREATING SPINAL CORD INJURY
WO - 05.02.2026
Int.Class G01N 33/68
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
 Appl.No PCT/US2025/040109 Applicant THE JOHNS HOPKINS UNIVERSITY Inventor AZAD, Tej
This document provides methods and materials for assessing and/or treating mammals (e.g., humans) having, or suspected of having, a spinal cord injury. For example, the presence of (a) spinal cord-derived cell free DNA (cfDNA) and/or (b) an elevated level of one or more of a fatty acid binding protein 3 (FABP3) polypeptide, a RE1-silencing transcription factor (REST) polypeptide, an interleukin 6 (IL-6) polypeptide, and a neurofilament, heavy polypeptide (NF-H) polypeptide in a fluid sample (e.g., a blood sample) obtained from a mammal (e.g., a human) can be used to identify that mammal as having a spinal cord injury. In some cases, a mammal (e.g., a human) identified as having a spinal cord injury as described herein can be administered one or more spinal cord injury treatments.
7.WO/2026/030672METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING COGNITIVE DECLINE
WO - 05.02.2026
Int.Class A61K 31/40
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
 Appl.No PCT/US2025/040262 Applicant ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI Inventor BLANCHARD, Joel
The disclosure provides methods of preventing or treating cognitive impairment or a decline of cognitive function in a subject in need thereof, the method comprising administering an effective amount of at least one compound to the subject, wherein administration of the compound reduces cellular and/or plasma membrane lipid content.
8.WO/2026/025301SAMPLE TREATMENT SYSTEM AND BIOLOGICAL SAMPLE TREATMENT METHOD
WO - 05.02.2026
Int.Class C12Q 1/6874
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6869Methods for sequencing
6874involving nucleic acid arrays, e.g. sequencing by hybridisation
 Appl.No PCT/CN2024/108583 Applicant MGI TECH CO., LTD. Inventor HU, Shuhuan
Provided are a sample treatment system and a biological sample treatment method. The sample treatment system comprises a tissue sample carrier and a slide carrier, the tissue sample carrier being used for supporting a biological tissue sample to be treated, and the slide carrier being used for carrying a slide to be tested. The sample treatment system further comprises: a sectioning device, which is movably arranged with respect to the tissue sample carrier and is used for sectioning a biological tissue sample to form a tissue section, the slide to be tested comprising a capture slide that is positioned with respect to the tissue sample carrier to receive a tissue section; a liquid adding device, the liquid adding device being movably arranged with respect to the tissue sample carrier and used for spraying a reagent layer with a predetermined thickness onto the capture slide, the liquid adding device at least comprising a first reagent assembly, and the first reagent assembly comprising a staining reagent and/or a permeabilizing reagent for treating a tissue section; and an optical module, the optical module being capable of performing image acquisition on the slide to be tested. The provided sample treatment system has improved degree of system integration and improved system efficiency.
9.WO/2026/026921USE OF RINL GENE AND ANTAGONIST THEREOF IN DIAGNOSIS AND TREATMENT OF HYPERURICEMIA
WO - 05.02.2026
Int.Class A61K 45/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
 Appl.No PCT/CN2025/111831 Applicant XIAMEN UNIVERSITY Inventor ZUO, Zhenghong
Use of the RINL gene and an antagonist thereof in the diagnosis and treatment of hyperuricemia. Use of the RINL gene or the encoded protein thereof. The RINL gene or the encoded protein thereof is: (1) used as a marker for the diagnosis, detection, or prognosis of hyperuricemia; (2) used for preparing a reagent or kit for diagnosing or detecting hyperuricemia; or (3) used for preparing a drug for preventing and/or treating hyperuricemia. RINL is an important relevant gene in the development and progression of hyperuricemia, and is also a potential treatment site for hyperuricemia. Inhibiting the expression of RINL significantly improves the ability of cells and mice to excrete uric acid.
10.WO/2026/030146MEDICAL DRAIN SENSORS AND SYSTEMS
WO - 05.02.2026
Int.Class A61M 27/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
27Drainage appliances for wounds, or the like
 Appl.No PCT/US2025/039235 Applicant PRESIDENT AND FELLOWS OF HARVARD COLLEGE Inventor SRINIVASAN, Shriya
The technology described herein is directed to devices, systems, kits, and methods relating to detecting the contents and characteristics of a fluid in a medical drain.
# -